Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors
Advanced Solid Tumor
DRUG: LM-108|DRUG: An Anti-PD-1 Antibody
AEs, Incidence of adverse events, 126 weeks|DLT, Incidence of dose-limiting toxicity (DLT), 21 days|SAE, Incidence of serious adverse event, 126 weeks|Incidence of clinical significant in laboratory examinations, Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function., 126 weeks
Incidence of anti-drug antibodies to LM-108, Incidence of anti-drug antibodies to LM-108, 126 weeks|Cmax, Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax) for LM-108, 126 weeks|Cmin, PK Parameter: Minimum Observed Concentration (Cmin) for LM-108, 126 weeks|Tmax, PK Parameter: Time of Maximum Observed Concentration (Tmax) for LM-108, 126 weeks|AUC, PK Parameter: Area Under the Concentration-time Curve (AUC) for LM-108, 126 weeks|Cmax,ss, PK Parameter: Steady State Maximum Concentration (Cmax,ss), 126 weeks|Cmin, ss, PK Parameter: Steady State Minimum Concentration (Cmin, ss), 126 weeks|CLss, PK Parameter: Systemic Clearance at Steady State (CLss), 126 weeks|Rac, PK Parameter: Accumulation Ratio (Rac), 126 weeks|t 1/2, PK Parameter: Elimination Half-life (t 1/2), 126 weeks|Vss, PK Parameter: Volume of Distribution at Steady-State (Vss), 126 weeks|DF, PK Parameter: Degree of Fluctuation (DF), 126 weeks
A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal).